147 related articles for article (PubMed ID: 10882608)
1. Conditional lethality of the diprotic weak bases chloroquine and quinacrine against Cryptococcus neoformans.
Harrison TS; Griffin GE; Levitz SM
J Infect Dis; 2000 Jul; 182(1):283-9. PubMed ID: 10882608
[TBL] [Abstract][Full Text] [Related]
2. Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation.
Levitz SM; Harrison TS; Tabuni A; Liu X
J Clin Invest; 1997 Sep; 100(6):1640-6. PubMed ID: 9294133
[TBL] [Abstract][Full Text] [Related]
3. Enhanced anticryptococcal activity of chloroquine in phosphatidylserine-containing liposomes in a murine model.
Khan MA; Jabeen R; Nasti TH; Mohammad O
J Antimicrob Chemother; 2005 Feb; 55(2):223-8. PubMed ID: 15590713
[TBL] [Abstract][Full Text] [Related]
4. Chloroquine antagonizes the proinflammatory cytokine response to opportunistic fungi by alkalizing the fungal phagolysosome.
Weber SM; Levitz SM
J Infect Dis; 2001 Mar; 183(6):935-42. PubMed ID: 11237811
[TBL] [Abstract][Full Text] [Related]
5. Gomesin, a peptide produced by the spider Acanthoscurria gomesiana, is a potent anticryptococcal agent that acts in synergism with fluconazole.
Barbosa FM; Daffre S; Maldonado RA; Miranda A; Nimrichter L; Rodrigues ML
FEMS Microbiol Lett; 2007 Sep; 274(2):279-86. PubMed ID: 17645524
[TBL] [Abstract][Full Text] [Related]
6. Determination of the pH of the Cryptococcus neoformans vacuole.
Harrison TS; Chen J; Simons E; Levitz SM
Med Mycol; 2002 Jun; 40(3):329-32. PubMed ID: 12146766
[TBL] [Abstract][Full Text] [Related]
7. [Determination of the minimum inhibitory concentration of fluconazole against Cryptococcus neoformans].
Fernández Andreu CM; Pimentel Turino T; Martínez Machín G; González Miranda M
Rev Cubana Med Trop; 1999; 51(1):55-7. PubMed ID: 10887558
[TBL] [Abstract][Full Text] [Related]
8. The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogen Cryptococcus neoformans.
Blasi E; Colombari B; Orsi CF; Pinti M; Troiano L; Cossarizza A; Esposito R; Peppoloni S; Mussini C; Neglia R
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):187-95. PubMed ID: 15364103
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of beta-1,3-glucan synthase and cell growth of Cryptococcus species by recombinant single-chain anti-idiotypic antibodies.
Selvakumar D; Miyamoto M; Furuichi Y; Komiyama T
J Antibiot (Tokyo); 2006 Feb; 59(2):73-9. PubMed ID: 16629406
[TBL] [Abstract][Full Text] [Related]
10. Chloroquine and the fungal phagosome.
Weber SM; Levitz SM; Harrison TS
Curr Opin Microbiol; 2000 Aug; 3(4):349-53. PubMed ID: 10972492
[TBL] [Abstract][Full Text] [Related]
11. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
Khyriem AB; Sujatha S; Parija SC
Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
[TBL] [Abstract][Full Text] [Related]
12. Antifungal activity of artemisinin derivatives.
Galal AM; Ross SA; Jacob M; ElSohly MA
J Nat Prod; 2005 Aug; 68(8):1274-6. PubMed ID: 16124777
[TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
[TBL] [Abstract][Full Text] [Related]
14. A synthetic peptide as a novel anticryptococcal agent.
Cenci E; Bistoni F; Mencacci A; Perito S; Magliani W; Conti S; Polonelli L; Vecchiarelli A
Cell Microbiol; 2004 Oct; 6(10):953-61. PubMed ID: 15339270
[TBL] [Abstract][Full Text] [Related]
15. In vitro synergic antifungal effect of MUC7 12-mer with histatin-5 12-mer or miconazole.
Wei GX; Bobek LA
J Antimicrob Chemother; 2004 May; 53(5):750-8. PubMed ID: 15073161
[TBL] [Abstract][Full Text] [Related]
16. Characterization of an ecto-ATPase activity in Cryptococcus neoformans.
Junior IC; Rodrigues ML; Alviano CS; Travassos LR; Meyer-Fernandes JR
FEMS Yeast Res; 2005 Jul; 5(10):899-907. PubMed ID: 15951247
[TBL] [Abstract][Full Text] [Related]
17. Influence of indinavir on virulence and growth of Cryptococcus neoformans.
Monari C; Pericolini E; Bistoni G; Cenci E; Bistoni F; Vecchiarelli A
J Infect Dis; 2005 Jan; 191(2):307-11. PubMed ID: 15609242
[TBL] [Abstract][Full Text] [Related]
18. Effects of microplusin, a copper-chelating antimicrobial peptide, against Cryptococcus neoformans.
Silva FD; Rossi DC; Martinez LR; Frases S; Fonseca FL; Campos CB; Rodrigues ML; Nosanchuk JD; Daffre S
FEMS Microbiol Lett; 2011 Nov; 324(1):64-72. PubMed ID: 22092765
[TBL] [Abstract][Full Text] [Related]
19. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.
Perkins A; Gomez-Lopez A; Mellado E; Rodriguez-Tudela JL; Cuenca-Estrella M
J Antimicrob Chemother; 2005 Dec; 56(6):1144-7. PubMed ID: 16282208
[TBL] [Abstract][Full Text] [Related]
20. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
